Page last updated: 2024-08-21

quinazolines and Cerebral Hemorrhage

quinazolines has been researched along with Cerebral Hemorrhage in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Chung, JI; Jalin, AMA; Jin, S; Joung, C; Ju, C; Kim, BS; Kim, WK; Lee, KS; Lee, S; Pahk, K; Ryu, JM; Song, HY	1
Chen, Z; Gao, F; Hua, Y; Keep, RF; Liu, F; Xi, G	1
Anderes, K; Camacho, LH; Culotta, KS; Davis, DW; Ekmekcioglu, S; Falchook, GS; Fu, S; Garrido-Laguna, I; George, GC; Hong, DS; Kurzrock, R; Liu, W; Moulder, SL; Naing, A; Percy Ivy, S; Piha-Paul, S; Tsimberidou, AM; Wen, Y; Wheler, JJ	1
Eguchi, Y; Ishikawa, M; Ito, S; Kobayashi, M; Moriya, K; Sugimoto, A	1

Trials

1 trial(s) available for quinazolines and Cerebral Hemorrhage

Article	Year
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer, 2014, Jul-15, Volume: 120, Issue:14 Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cerebral Hemorrhage; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Quinazolines; Sarcoma; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A	2014

Article

Year

Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.

Cancer, 2014, Jul-15, Volume: 120, Issue:14

Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cerebral Hemorrhage; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms; Neoplastic Cells, Circulating; Quinazolines; Sarcoma; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A

2014

Other Studies

3 other study(ies) available for quinazolines and Cerebral Hemorrhage

Article	Year
The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia. International journal of molecular sciences, 2022, Jan-26, Volume: 23, Issue:3 Topics: Acetamides; Animals; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Endothelial Cells; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Matrix Metalloproteinases; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator	2022
Hydrocephalus after intraventricular hemorrhage: the role of thrombin. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014, Volume: 34, Issue:3 Topics: Animals; Blood-Brain Barrier; Cerebral Hemorrhage; Cerebral Ventricles; Hydrocephalus; Injections, Intraventricular; Magnetic Resonance Imaging; Male; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, PAR-1; Thrombin	2014
[Prophylactic effect of EG-1088 on cerebrovascular lesions of stroke-prone spontaneously hypertensive rats]. Iyo Kizai Kenkyujo hokoku. Reports of the Institute for Medical and Dental Engineering, Tokyo Medical and Dental University, 1982, Volume: 16 Topics: Animals; Antihypertensive Agents; Cerebral Arterial Diseases; Cerebral Hemorrhage; Cerebral Infarction; Cerebrovascular Disorders; Diet, Atherogenic; Hypertension; Intracranial Arteriosclerosis; Quinazolines; Rats; Rats, Inbred Strains	1982